[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505354":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":47,"responsibleParty":64,"collaborators":67,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":32,"enrollmentInfo":97,"targetDuration":32,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":49,"whyStopped":32,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","ACTIVE_COMPARATOR","Patients will be given Cholecalciferol (produced by Xymogen Company) 4000 U (2 capsules) per day",[13],"Drug: Cholecalciferol",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Patients will receive placebo, 2 capsules per day.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cholecalciferol","Patients in the intervention group will receive oral cholecalciferol 4000U per day.",[9],[27],"Natural Vitamin D3",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Patients in the control group will receive placebo 2 capsules per day.",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Jie Dong","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Jie Dong, Professor","CONTACT","13911841538","jie.dong@bjmu.edu.cn",{"name":44,"role":40,"phone":45,"phoneExt":32,"email":46},"Zhikai Yang","13671248465","seapollar@126.com",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":56,"coordinates":57},"Point",[58,59],116.39723,39.9075,{"lat":59,"lon":58},[62],{"name":35,"role":40,"phone":63,"phoneExt":32,"email":42},"010-83572532",{"type":36,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Dong Jie","Director of PD center",[68,70,72,74,76,79,81,83,85],{"name":69,"class":6},"Peking University Third Hospital",{"name":71,"class":6},"Peking University People's Hospital",{"name":73,"class":6},"Beijing Haidian Hospital",{"name":75,"class":6},"Peking University Shenzhen Hospital",{"name":77,"class":78},"Beijing Fangshan District Hospital of Traditional Chinese Medicine","UNKNOWN",{"name":80,"class":6},"Peking University International Hospital",{"name":82,"class":6},"Beijing Tsinghua Changgeng Hospital",{"name":84,"class":6},"Beijing Anzhen Hospital",{"name":86,"class":6},"Capital Medical University","100505354","phase-4-oral-vitamin-d-supplementation-prevent-peritoneal-dialysis-related-peritonitis-100505354",false,"NCT05860270","Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis","The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis, a Multicenter Randomized Controlled Trial","VD-PD","Inclusion Criteria:\n\n* Medically stable and receiving peritoneal dialysis for \\> 1 month\n* Older than 18 years old\n* Serum 25(OH)D \\\u003C 30ng\u002Fml\n* Adequate dialysis on evaluation with weekly Kt\u002FV ≥ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms\n\nExclusion Criteria:\n\n* Receive Vitamin D2\u002FD3 during the previous 1 month (revised time: 2023-7-11) ;\n* History of allergic reaction to Cholecalciferol;\n* Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV\u002FAIDS;\n* Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;\n* A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months;\n* History of kidney transplant;\n* Hemodialysis combined with peritoneal dialysis currently;\n* Pregnant or breastfeeding;\n* Not suitable enrolled assessed by researchers, including patients who could not regular follow-up","ALL","19 Years",{"count":98,"type":99},176,"ESTIMATED","INTERVENTIONAL",[102],"PHASE4","This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.",[105,106],"Peritoneal Dialysis-associated Peritonitis","Vitamin D Deficiency",[108,109,23],"Peritoneal dialysis","Peritonitis","2024-08-05",{"date":112,"type":113},"2024-08-06","ACTUAL",{"date":115,"type":113},"2023-06-15",{"date":117,"type":99},"2026-05-31",{"name":5,"class":6},1]